Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Videos [543]
News [1580]
Articles [79]
Editorials [2]
Conferences [74]
elearning [5]

Phase I and II trials focus on drug combination slowing development of resistance inhibiting BRAF

Prof Yossef Yarden - Weizmann Institute of Science, Israel.
Phase I and II trials focus on drug combination slowing development of resistance inhibiting BRAF ( Prof Yossef Yarden - Weizmann Institute of Science, Israel. )
29 Sep 2012

The immuno side of melanoma

Dr Antoni Ribas – UCLA Jonsson Comprehensive Cancer Center, Los Angeles, USA
The immuno side of melanoma ( Dr Antoni Ribas – UCLA Jonsson Comprehensive Cancer Center, Los Angeles, USA )
16 Jul 2012

MEK inhibitor, trametinib, improves progression free survival in melanoma

Dr Caroline Robert – Institute Gustave Roussy, Paris, France
MEK inhibitor, trametinib, improves progression free survival in melanoma ( Dr Caroline Robert – Institute Gustave Roussy, Paris, France )
18 Jun 2012

Treating metastatic melanoma with vemurafenib

Dr Paul Chapman – Memorial Sloan-Kettering Cancer Center, New York, USA
Treating metastatic melanoma with vemurafenib ( Dr Paul Chapman – Memorial Sloan-Kettering Cancer Center, New York, USA )
15 Jun 2012

New BRAF inhibitor dabrafenib delays disease progression in advanced melanoma

Dr Axel Hauschild - Universitaetsklinikum Schleswig-Holstein, Germany
New BRAF inhibitor dabrafenib delays disease progression in advanced melanoma ( Dr Axel Hauschild - Universitaetsklinikum Schleswig-Holstein, Germany )
4 Jun 2012

New MEK inhibitor, trametinib, improves survival in advanced melanoma

Dr Caroline Robert - Institut Gustave Roussy, Villejuif, France
New MEK inhibitor, trametinib, improves survival in advanced melanoma ( Dr Caroline Robert - Institut Gustave Roussy, Villejuif, France )
4 Jun 2012

Early results from new PD-1 targeted immune therapy

Dr Suzanne Topalian - Johns Hopkins University School of Medicine, Baltimore, USA
Early results from new PD-1 targeted immune therapy ( Dr Suzanne Topalian - Johns Hopkins University School of Medicine, Baltimore, USA )
2 Jun 2012

Implementing symptom guidelines

Anita Margulies - EONS and the Swiss Oncology Nursing Society
Implementing symptom guidelines ( Anita Margulies - EONS and the Swiss Oncology Nursing Society )
14 May 2012

Impact and management of malignant wounds

Dr Betina Lund-Nielsen - University of Copenhagen, Denmark
Impact and management of malignant wounds ( Dr Betina Lund-Nielsen - University of Copenhagen, Denmark )
10 May 2012

The evolving role of immunotherapy in oncology

Prof Gordon McVie; Prof Alexander Eggermont; Dr Kim Margolin; Prof Micheal Maio; Prof Thomas Lynch
The evolving role of immunotherapy in oncology ( Prof Gordon McVie; Prof Alexander Eggermont; Dr Kim Margolin; Prof Micheal Maio; Prof Thomas Lynch )
1 Nov 2011

Latest in renal carcinoma

Dr James Larkin - The Royal Marsden, London, UK
Latest in renal carcinoma ( Dr James Larkin - The Royal Marsden, London, UK )
21 Oct 2011

Vemurafenib improves survival in melanoma with BRAF V600E mutation

Dr Grant McArthur - Peter MacCallum Cancer Centre, Melbourne, Australia
Vemurafenib improves survival in melanoma with BRAF V600E mutation ( Dr Grant McArthur - Peter MacCallum Cancer Centre, Melbourne, Australia )
21 Oct 2011

More from ecancer

Register with ecancer to receive our newsletter

Register here

Explore patient resources at ecancerpatient

Visit site

Find out more about ecancer and the work we do

About ecancer

Support ecancer's work by making a donation